Opening the Sources of Drug Discovery

Bernard Munos

Mr. Munos is the founder and chief apostle of InnoThink, a partnership dedicated to bringing evidence-based innovation models to the pharmaceutical industry and its stakeholders. Before that, he was advisor for corporate strategy at Eli Lilly and Company, where he focused on disruptive innovation and the radical redesign of the industry R&D model. His research, which has been published in Nature and Science, has helped stimulate a broad rethinking of the pharmaceutical business model by companies, investors, policymakers, regulators, and patient advocates.

He has presented his findings at numerous meetings sponsored by the National Academies, the Institute of Medicine, the President's Cancer Panel, the NIH Leadership Forum, the World Health Organization, the OECD, the Kauffman Foundation, the U.S. Patent and Trademark Office, Genome Canada, the American Chemical Society, and the Council for American Medical Innovation as well as leading universities and think-tanks in the U.S. and Europe.

He received his MBA from Stanford University and holds other graduate degrees in economics and animal science from the University of California at Davis and the Institut National Agronomique in Paris, France.

David Shaywitz Ph.D.

Dr. Shaywitz is a graduate of Harvard College (summa cum laude), and received his MD from the Health Sciences and Technology program at Harvard Medical School and MIT, and his PhD from the Department of Biology at MIT. He trained in internal medicine and endocrinology at MGH, and conducted his post-doctoral research in the Melton lab at Harvard.

He gained experience in early clinical drug development in the Department of Experimental Medicine at Merck, then joined the Boston Consulting Group's Healthcare and Corporate Development practices, where he focused on strategy and organizational design. He is currently Director of Strategic and Commercial Planning at Theravance, a publicly-held drug development company in South San Francisco.

Dr. Shaywitz is a co-founder (with Dennis Ausiello) of the Harvard PASTEUR program, a translational research initiative at Harvard Medical School (www.pasteur.harvard.edu). He is also a founding advisor of Sage, a non-profit medical research initiative (founded by Eric Schadt and Stephen Friend) emphasizing networks and open innovation (www.sagebase.org).

For the last fifteen years, Dr. Shaywitz has contributed commentaries about medicine, science, innovation, and business to a number of popular publications, including The New York Times, The Washington Post, The Wall Street Journal, and The Financial Times. He currently is a regular contributor to Forbes.com.

Dr. Shaywitz is an Adjunct Scholar at the American Enterprise Institute.

Mat Todd Ph.D.

Mat Todd was born in Manchester, UK in 1973. He was educated at Cambridge University, and stayed there for a PhD with Professor Chris Abell where he worked on encoding and linker strategies for combinatorial chemistry. He received a Wellcome Trust International Travelling Research Fellowship for his postdoctoral studies with Professor Paul Bartlett at the University of California, Berkeley where he worked on divergent syntheses of peptidomimetic scaffolds.

He was appointed Fellow in Chemistry and College Lecturer at New Hall College, Cambridge in 2000, and then joined the faculty at Queen Mary, University of London in 2001. In 2005 he moved to the University of Sydney, where he is currently Senior Lecturer in Organic Chemistry.